Send me real-time posts from this site at my email

Trading List: Feb. 3 - Updates & Analyst Actions - HZNP

Notable updates, news, or analysts actions from our trading lists followed by 'Our Take'.

Viela deal could be 'transformative' for Horizon growth, says Jefferies

Jefferies analyst David Steinberg said Horizon Therapeutics' (HZNP) deal to acquire Viela Bio (VIE) looks well aligned with the former's focus in rare diseases and offers a deep biologics pipeline that could accelerate growth in the second half of this decade. The analyst, who thinks owning Viela "could be transformative" to Horizon's long-term growth, has a Buy rating and $103 price target on Horizon shares.

Our Take:  "Horizon has been a huge win for our readers last year, about tripling off its lows. We see this as a volatile, but highly profitable company with a growing pipeline. A good trading stock and longer-term growth play in the biotech sector."

$HZNP, Horizon Therapeutics Public Limited Company / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so).

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.


Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue